Asset Details
Do you wish to reserve the book?
ResMAP—a saturation mutagenesis platform enabling parallel profiling of target-specific resistance-conferring mutations in Plasmodium
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ResMAP—a saturation mutagenesis platform enabling parallel profiling of target-specific resistance-conferring mutations in Plasmodium
Do you wish to request the book?
ResMAP—a saturation mutagenesis platform enabling parallel profiling of target-specific resistance-conferring mutations in Plasmodium
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ResMAP—a saturation mutagenesis platform enabling parallel profiling of target-specific resistance-conferring mutations in Plasmodium
2024
Overview
An increase in treatment failures for malaria highlights an urgent need for new tools to understand and minimize the spread of drug resistance. We describe the development of a RESistance Mapping And Profiling (ResMAP) platform for the identification of resistance-conferring mutations in Plasmodium spp, the causative agent of malaria. Saturation mutagenesis was used to generate a mutation library containing all conceivable mutations for a region of the antimalarial-binding site of a promising drug target, Plasmodium falciparum lysyl tRNA synthetase ( Pf KRS). Screening of this high-coverage library with characterized Pf KRS inhibitors revealed multiple resistance-conferring substitutions including several clinically relevant mutations. Genetic validation of these mutations confirmed resistance of up to 100-fold and computational modeling dissected their role in drug resistance. We discuss potential applications of this data including the potential to design compounds that can bypass the most serious resistance mutations and future resistance surveillance.
Publisher
American Society for Microbiology
Subject
/ Antimalarials - pharmacology
/ Enzymes
/ Humans
/ Lysine-tRNA Ligase - genetics
/ Lysine-tRNA Ligase - metabolism
/ Malaria
/ Mutation
/ Plasmodium falciparum - drug effects
/ Plasmodium falciparum - enzymology
/ Plasmodium falciparum - genetics
/ Plasmodium knowlesi - drug effects
/ Plasmodium knowlesi - enzymology
/ Plasmodium knowlesi - genetics
/ tRNA
